Oleuropein and hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with ERK1/2 activation

Molecular Nutrition and Food Research

Volumn 54, Issue 6, 2010, Pages 833-840

  Sirianni, Rosa ^a   Chimento, Adele ^a   de Luca, Arianna ^a   Casaburi, Ivan ^a   Rizza, Pietro ^a   Onofrio, Arianna ^a   Iacopetta, Domenico ^a   Puoci, Francesco ^a   Andò, Sebastiano ^a   Maggiolini, Marcello ^a   Pezzi, Vincenzo ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Cancer; Estrogen; Hydroxytyrosol; MCF 7; Oleuropein

Indexed keywords

3,4-DIHYDROXYPHENYLETHANOL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESR1 PROTEIN, HUMAN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HYDROXYTYROSOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLEUROPEIN; PHENETHYL ALCOHOL; PROTEIN KINASE INHIBITOR; PYRAN DERIVATIVE;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHENYLETHYL ALCOHOL; PROTEIN KINASE INHIBITORS; PYRANS; TRANSCRIPTIONAL ACTIVATION;

EID: 77953963937     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200900111     Document Type: Article

References (46)

1. Landis, S. H., Murray, T., Bolden, S., Wingo, P. A., Cancer statistics. CA Cancer J. Clin. 1999, 49, 8-31.
2. Jensen, E. V., Ann, N. Y., Steroid hormones, receptors, and antagonists. Acad. Sci. 1996, 784, 1-17.
3. Levin, E. R., Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 2005, 19, 1951-1959.
4. Hong, W. K., General keynote: the impact of cancer chemoprevention. Gynecol. Oncol. 2003, 88, S56-S58.
5. Owen, R. W., Giacosa, A., Hull, W. E., Haubner, R. et al., Bartsch, H. Olive-oil consumption and health: the possible role of antioxidants. Lancet Oncol. 2000, 1, 107-112.
6. Vissers, M. N., Zock, P. L., Roodenburg, A. J. C., Leenen, R., Katan, M. B., Olive oil phenols are absorbed in humans. J. Nutr. 2002, 132, 409-417.
7. Kardono, L. B., Tsauri, S., Padmawinata, K., Pezzuto, J. M., Kinghorn, A. D., Cytotoxic constituents of the bark of plumeria rubra collected in Indonesia. J. Nat. Prod. 1990, 53, 1447-1455.
8. Hirano, T., Fukuoka, K., Oka, K., Naito, T. et al., Antiproliferative activity of mammalian lignan derivatives against the human breast carcinoma cell line, ZR-75-1. Cancer Invest. 1990, 8, 595-602.
9. Thompson, L. U., Seidl, M. M., Rickard, S. E., Orcheson, L. J., Fong, H. H., Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr. Cancer 1996, 26, 159-165.
10. Fabiani, R., De Bartolomeo, A., Rosignoli, P., Servili, M. et al., Virgin olive oil phenols inhibit proliferation of human promyelocytic leukemia cells (HL60) by inducing apoptosis and differentiation. J. Nutr. 2006, 136, 614-619.
11. Goulas, V., Exarchou, V., Troganis, A. N., Psomiadou, E. et al., Phytochemicals in olive-leaf extracts and their antiproliferative activity against cancer and endothelial cells. Mol. Nutr. Food Res. 2009, 53, 600-608.
12. Adlercreutz, H., Bannwart, C., Wähälä, K., Mäkelä, T. et al., Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J. Steroid Biochem. Mol. Biol. 1993, 44, 147-156.
13. Bunone, G., Briand, P. A., Miksicek, R. J., Picard, D., Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
14. Razandi, M., Pedram, A., Rosen, E. M., Levin, E. R., BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol. Cell. Biol. 2004, 24, 5900-5913.
15. Reddy, K. B., Glaros, S., Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo. Int. J. Oncol. 2004, 30, 971-975
16. Subramanian, A., Salhab, M., Mokbel, K., Oestrogen producing enzymes and mammary carcinogenesis: a review. Breast Cancer Res. Treatment 2008, 111, 191-202.
17. Henderson, B. E., Ross, R., Bernstein, L., Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal foundation award lecture. Cancer Res. 1988, 48, 246-253.
18. Beato, M., Herrlich, P., Schutz, G., Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83, 851-857.
19. Parker, M. G., White, R., Nuclear receptors spring into action. Nat. Struct. Biol. 1996, 3, 113-115.
20. McKenna, N. J., Lanz, R. B., O'Malley, B. W., Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20, 321-344.
21. Anstead, G. M., Carlson, K. E., Katzenellenbogen, J. A., The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997, 62, 268-303.
22. Blair, R. M., Fang, H., Branham, W. S., Hass, B. S. et al., The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol. Sci. 2000, 54, 138-153.
23. Sohoni, P., Sumpter, J. P., Several environmental oestrogens are also anti-androgens. J. Endocrinol. 1998, 158, 327-339.
24. Akingbemi, B. T., Hardy, M. P., Oestrogenic and antiandrogenic chemicals in the environment: effects on male reproductive health. Ann. Med. 2001, 33, 391-403.
25. Maggiolini, M., Bonofiglio, D., Marsico, S., Panno, M. L. et al., Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol. Pharmacol. 2001, 60, 595-602.
26. Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E. et al., Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and b. Endocrinology 1997, 138, 863-870.
27. Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E. et al., Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998, 54, 105-112.
28. Santagati, S., Gianazza, E., Agrati, P., Vegeto, E. et al., Oligonucleotide squelching reveals the mechanism of estrogen receptor autologous down-regulation. Mol. Endocrinol. 1997, 11, 938-949.
29. Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A. et al., Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 1996, 15, 1292-1300.
30. Migliaccio, A., Piccolo, D., Castoria, G., Di Domenico, M. et al., Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998, 17, 2008-2018.
31. Castoria, G., Migliaccio, A., Bilancio, A., Di Domenico, M. et al., PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001, 20, 6050-6059.
32. Castoria, G., Migliaccio, A., Di Domenico, M., Lombardi, M. et al., Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 Cells. Mol. Cell. Biol. 2004, 24, 7643-7653.
33. Migliaccio, A., Di Domenico, M., Castoria, G., Nanayakkara, M. et al., Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res. 2005, 65, 10585-10593.
34. Carpenter, C. L., Cantley, L. C., Phosphoinositide 3-kinase and the regulation of cell growth. Biochim. Biophys. Acta 1996, 1288, M11-M16.
35. Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., Prossnitz, E. R., A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307, 1625-1630.
36. Thomas, P., Pang, Y., Filardo, E. J., Dong, J., Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146, 624-632.
37. Filardo, E. J., Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J.Steroid Biochem. Mol. Biol. 2002, 80, 231-238.
38. Filardo, E. J., Quinn, J. A., Bland, K. I., Frackelton, A. R. Jr., Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14, 1649-1660.
39. Prossnitz, E. R., Arterburn, J. B., Smith, H. O., Oprea, T. I. et al., Estrogen signaling through the transmembrane G protein coupled receptor GPR30. Annu. Rev. Physiol. 2008, 70, 165.
40. Maggiolini, M., Vivacqua, A., Fasanella, G., Recchia, A. G. et al., The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 2004, 279, 27008-27016.
41. Martinez-Gonzalez, J., Rodriguez-Rodriguez, R., Gonzalez-Diez, M., Rodriguez, C. et al., Oleanolic acid induces prostacyclin release in human vascular smooth muscle cells through a cyclooxygenase-2-dependent mechanism. J. Nutr. 2008, 138, 443-448.
42. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H. et al., Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262, 5592-5595.
43. Albanito, L., Lappano, R., Madeo, A., Chimento, A. et al., G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ. Health Perspect. 2008, 116, 1648-1655.
44. Weinbrenner, T., Fito, M., de la Torre, R., Saez, G. T. et al., Olive oils high in phenolic compounds modulate oxidative/ antioxidative status in men. J. Nutr. 2004, 134, 2314-2321.
45. Miro-Casas, E., Covas, M.I., Farre, M., Fito, M. et al., Hydroxytyrosol disposition in humans. Clin. Chem. 2003, 49, 945-952.
46. Rietjens, S. J., Bast, A., de Vente, J., Haenen, G. R. M. M., The olive oil antioxidant hydroxytyrosol efficiently protects against the oxidative stress-induced impairment of the NO response of isolated rat aorta. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, 1931-1936.